

# 3-Aminobenzamide

Catalog No: tcsc0157



## Available Sizes

**Size:** 200mg

**Size:** 500mg



## Specifications

**CAS No:**

3544-24-9

**Formula:**

$C_7H_8N_2O$

**Pathway:**

Epigenetics;Cell Cycle/DNA Damage

**Target:**

PARP;PARP

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O : ≥ 11.11 mg/mL (81.60 mM)

**Alternative Names:**

PARP-IN-1

**Observed Molecular Weight:**

136.15


## Product Description

3-Aminobenzamide is a potent inhibitor of **PARP** with **IC<sub>50</sub>** of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.

IC50 & Target: IC50: 50 nM (PARP)<sup>[1]</sup>

**In Vitro:** 3-Aminobenzamide (>1  $\mu$ M) causes more than 95% inhibition of PARP activity without significant cellular toxicity. INO-1001 significantly sensitizes CHO cells by blocking most of the DNA repair occurring between radiation fractions<sup>[1]</sup>. 3-Aminobenzamide significantly improves endothelial function by enhancing the acetylcholine-induced, endothelium-dependent, nitric oxide mediated vasorelaxation after exposure with 400  $\mu$ M H<sub>2</sub>O<sub>2</sub><sup>[2]</sup>.

**In Vivo:** In a *db/db* (*Leprdb/db*) mouse model, 3-Aminobenzamide ameliorates diabetes-induced albumin excretion and mesangial expansion, and also decreases diabetes-induced podocyte depletion<sup>[3]</sup>. 3-Aminobenzamide (1.6 mg/kg via intracerebral injection) prevents NAD<sup>+</sup> depletion and improves water maze performance after controlled cortical impact (CCI) in mice<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!